Full Coverage

Gilead Sciences enters into $750 million agreement with Kymera Therapeutics

Top news

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

7 hours ago

Kymera suffers Sanofi setback but secures $750M Gilead deal

5 hours ago

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

4 hours ago

By Mariam E Sunny & Shailesh Kuber

All coverage

Gilead Sciences (GILD) Anticipates 2025 EPS Impact Due to Kymera Transaction | GILD Stock News

7 hours ago

Kymera Therapeutics Advances KT-485 in Sanofi Collaboration

7 hours ago

Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera

6 hours ago

By Tristan Cesar Manalac

Gilead Sciences, Kymera Therapeutics to Collaborate on Cancer Program

7 hours ago

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

2 hours ago

By Gwendolyn Wu

Investing.com Canada

Sanofi to advance Kymera’s oral IRAK4 degrader KT-485 to clinical testing

7 hours ago

The Pharma Letter

Kymera inks licensing deal with Gilead and updates on Sanofi accord

5 hours ago

Kymera Shrugs Off Sanofi Bust With Gilead Deal - But There Are Caveats (NASDAQ:KYMR)

1 hour ago

By Edmund Ingham

FirstWord Pharma

Kymera snags Gilead as new partner, while Sanofi opts for next-gen IRAK4 degrader

8 hours ago

Gilead Teams Up With Kymera To Develop Cancer Therapies

5 days ago

Proactive financial news

Gilead partners with Kymera to develop novel cancer therapy

3 hours ago

By Emily Jarvie

Gilead and Kymera in pact to develop cancer drugs

3 hours ago

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

6 hours ago

Gilead, Kymera Launch Collaboration on Novel Oral CDK2 Degraders for Solid Tumors

2 hours ago

By Don Tracy

Pharmaceutical Technology

Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal

2 hours ago

By Robert Barrie

Kymera inks deal with Gilead as partnership with Sanofi faces a switch-up

3 hours ago

By Lei Lei Wu

Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders

7 hours ago

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

5 hours ago

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

5 hours ago

By Vandana Singh

Kymera Announces Sanofi to Advance KT-485 Into Clinical Testing

7 hours ago

Gilead sees Kymera deal lowering 2025 EPS by 2c-3c

7 hours ago

Kymera Therapeutics Partners with Gilead for Oncology Treatment

7 hours ago

GILD Enters New Partnership with Kymera for CDK2 Degrader Develo

3 hours ago

Gilead (GILD) Enters Agreement with Kymera to Enhance Cancer Treatment | GILD Stock News

7 hours ago

Gilead and Kymera partner on novel cancer drug development

7 hours ago

Gilead, Kymera enter license agreement for molecular glue degrader program

7 hours ago

Investing.com India

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit

3 hours ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update | KYMR Stock News

7 hours ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Opt

7 hours ago

Gilead (GILD) Enters Agreement with Kymera for Novel Cancer Treatment | GILD Stock News

7 hours ago

Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

7 hours ago

Search

Clear search

Close search

Google apps

Main menu